Trial Profile
A Multi-Centre, Randomized, Double Blind Cross-Over Study to Assess the Non-Inferiority of GW685698X 200mcg Once Daily and 100mcg Twice Daily in Adult and Adolescent Patients With Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Fluticasone furoate (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 22 Sep 2010 Results presented at the European Respiratory Society congress, according to a GSK media release.
- 03 Dec 2008 Status changed from recruiting to active, no longer recruiting.
- 26 Nov 2008 Planned number of patients changed from 750 to 375.